Pharma Giant Roche Halts Investment in Germany Amid Government Budget Cuts

Swiss pharmaceutical leader Roche has announced a pause on all investments in Germany, citing concerns over the government's recent healthcare savings policies that have damaged trust in the industry. Roche CEO Daniel Steiners revealed in an interview that these short-term fiscal measures contradict the government's stated goal of strengthening the pharmaceutical sector, specifically pointing to the GKV stabilization law which he says imposes burdens on companies rather than addressing systemic issues.

Roche, which employs over 18,000 people in Germany and is in the process of expanding its Penzberg site, sees this move as necessary while awaiting clearer, more supportive policy conditions. Steiners praised U.S. industrial policy for fostering investment, urging Europe to adopt similar strategies.

The investment freeze comes amid wider pharmaceutical industry frustration, with other companies like Eli Lilly halving planned investments of €2.5 billion in Rhineland-Palatinate, Boehringer Ingelheim scrapping €900 million in expenditures, and Pfizer also reconsidering investment plans—all due to the government's increased savings requirements and demands for higher manufacturer discounts to statutory health insurers.

Roche remains optimistic about its future revenue, projecting growth of 16.3 billion Swiss francs from 2025 to 2030 to offset 6.2 billion francs in patent expirations. The company is shifting its research focus towards artificial intelligence, opening a new innovation center in Boston dedicated to cardiovascular and metabolic diseases and AI-driven drug development.

This development poses a significant challenge for Chancellor Friedrich Merz's administration, which is actively promoting Germany as an investment hub despite current pharmaceutical sector discontent. The situation highlights a disconnect between policy and industry needs, raising concerns about Germany's competitiveness as a destination for high-value pharmaceutical investments.